Financial Results

Q-Line Biotech Reports Strong FY26 Performance; PAT Rises 56.75%, EBITDA Up 38.97%

NSE

qline

BSE

not listed

Q-Line Biotech Limited reported robust FY26 financial performance with revenue growing 9.13% YoY to ₹341.74 crore, EBITDA increasing 38.97% to ₹98.05 crore, and Profit After Tax surging 56.75% to ₹56.71 crore. The company also delivered strong H2 FY26 momentum, driven by manufacturing expansion, higher sales of manufactured reagents, operating leverage, and margin improvement.

PRICE-SENSITIVE TRIGGER

Event: FY26 Audited Financial Results Announcement

Type: Financial Results

Impact: Positive

Immediate Effect: The results highlight significant profitability expansion, improving operating leverage, stronger manufacturing contribution, and positive management guidance of 30–35% revenue growth for FY27.

Key Metrics:

FY26 Revenue: ₹341.74 Cr (+9.13% YoY)
FY26 EBITDA: ₹98.05 Cr (+38.97% YoY)
FY26 EBITDA Margin: 28.69% (FY25: 22.53%)
FY26 PBT: ₹73.54 Cr (+42.23% YoY)
FY26 PBT Margin: 21.52%
FY26 PAT: ₹56.71 Cr (+56.75% YoY)
FY26 PAT Margin: 16.60%

H2 FY26 Performance:

FY26 Revenue: ₹341.74 Cr (+9.13% YoY)
FY26 EBITDA: ₹98.05 Cr (+38.97% YoY)
FY26 EBITDA Margin: 28.69% (FY25: 22.53%)
FY26 PBT: ₹73.54 Cr (+42.23% YoY)
FY26 PBT Margin: 21.52%
FY26 PAT: ₹56.71 Cr (+56.75% YoY)
FY26 PAT Margin: 16.60%

Highlight:

Reagents and diagnostic kits contributed approximately 69% of total revenue.
Sales of manufactured reagents increased by nearly 70% during FY26.
EBITDA margin expanded by over 600 basis points to 28.69%.
More than 50% of laboratory equipment is now manufactured domestically through technology collaborations.

What Happened ?

Q-Line Biotech announced its audited financial results for the half year and full year ended March 31, 2026, reporting strong growth across revenue, profitability, and margins.

The company benefited from increased sales of manufactured diagnostic reagents, improved product mix, higher operating efficiencies, and reduced dependence on traded products. H2 FY26 performance accelerated significantly compared to H1 FY26, demonstrating strong operating leverage and improving profitability.

Management also issued FY27 guidance, targeting revenue growth of 30–35% year-on-year, supported by IPO-funded expansion initiatives, manufacturing scale-up, export growth, and increasing installed instrument base.

Key Details

Business Developments and Growth Initiatives:

Product licenses have been obtained for five products at the new Unit-4 manufacturing facility.
Commercial production of Clinical Chemistry Reagents is expected to commence by Q2 FY27, subject to regulatory approvals.
The company has initiated implementation of a new ERP platform aimed at strengthening automation, operational controls, and data-driven decision-making.
PwC has been engaged to enhance Internal Financial Controls (IFC) and Internal Controls over Financial Reporting (ICFR).
An International Business Manager has been appointed in Dubai to accelerate export expansion.
Export sales contributed approximately ₹1.18 crore during FY26.
Distributor agreements have been signed across 7–8 countries as of March 2026.
Management expects export revenues to increase nearly fivefold during FY27.
The company plans to initiate CDMO operations through manufacturing of Selectra Pro M and Microlab 300 instruments.
Exclusive technology collaborations with Vital Scientific and Boule Sweden AB support instrument and reagent manufacturing expansion.
Installed base of Selectra Pro M Fully Automatic Biochemistry Analysers has crossed 1,550 units.
Commercialization of the Electrolyte Analyzer has been completed.
Microlab 300 launch remains on track for Q2 FY27.

Note:

The company is transitioning toward a higher-margin manufacturing-led business model while simultaneously expanding exports, instrumentation, and contract manufacturing opportunities.

Risk Analysis

Summary:

Despite strong earnings momentum, successful execution of manufacturing expansion, regulatory approvals, export scaling, and commercialization initiatives remains critical for sustaining projected growth.

Key Risks:

Commercial production at Unit-4 remains subject to regulatory approvals.
Export growth targets depend on successful execution of international distributor partnerships.
ERP implementation and governance initiatives require smooth execution.
Diagnostic industry competition may affect pricing and market share expansion.
Commercial success of new products and CDMO operations remains execution-dependent.
International expansion introduces operational and compliance risks.

Worst Case Scenario:

Delays in regulatory approvals, slower export growth, or weaker adoption of new products could impact FY27 growth targets and profitability expectations.

Risk Level: Moderate

Company Commentary

Management described FY26 as a transformative year driven by successful capitalization of its largest manufacturing facility in Lucknow.
Sales of manufactured reagents increased nearly 70%, reflecting the company’s strategy of strengthening in-house manufacturing capabilities.
The company highlighted significant progress in diagnostic instruments with over 1,550 Selectra Pro M installations.
Management believes recent investments have strengthened profitability, operating leverage, and competitive positioning.
The company remains focused on manufacturing expansion, innovation, product development, and long-term value creation.
FY27 revenue growth guidance has been set at approximately 30–35% year-on-year.
Growth is expected to be supported by working capital deployment, sales force expansion, wider geographic penetration, export growth, and increasing recurring reagent revenues.

Official Exchange Filing: Q-Line Biotech Limited

Support our work by sharing